27 Iajps27112017 PDF
27 Iajps27112017 PDF
27 Iajps27112017 PDF
PHARMACEUTICAL SCIENCES
http://doi.org/10.5281/zenodo.1042737
Abstract:
Ramipril is an anti-hypertensive drug, a category of ACE inhibitor that inhibit the actions of angiotensin converting
enzyme (ACE), thereby decreasing the production of angiotensin II and decreasing the breakdown of bradykinin.
The decrease in an enzyme angiotensin II results in relaxation of arteriole smooth muscle leading to a lowering the
total peripheral resistance, reducing blood pressure(BP) as the blood is pumped through widened. Ramipril, a
precursor or prodrug, is converted to the active metabolite ramiprilat by carboxylesterase. It is mostly excreted by
the kidneys. Its half-life is 3-16 hours and is prolonged by heart and liver failure, as well as kidney failure. The
medication used alone or in combination with other medications to treat high blood pressure. The drug is also used
to reduce the risk of stroke and heart attack in patients at risk for these types of problems and to improve survival in
patients with heart failure after a heart attack.
Key words: Ramipril, Ramiprilat, Angiotensin II, Bradykinin, Carboxylesterase, Blood pressure.
Correspondence address:
QR code
M.Hareesh Reddy,
Associate Professor,
Shadan College of Pharmacy, Peerancheru,
Himayatsagar Road, Hyderabad.
E-mail: masireddyharish@gmail.com
Please cite this article in press as M.Hareesh Reddy and Dr.A. Sambasiva Rao, A Comprahensive Review of
Pharmacological and Therapeutical Activities of Anti-Hypertensive Drug Ramipril, Indo Am. J. P. Sci, 2017;
4(11).
www.iajps.com Page 1
IAJPS 2017, 4 (11), 3951-3953 M.Hareesh Reddy and A. Sambasiva Rao ISSN 2349-7750
www.iajps.com Page 2
IAJPS 2017, 4 (11), 3951-3953 M.Hareesh Reddy and A. Sambasiva Rao ISSN 2349-7750
www.iajps.com Page 3